How Popular Will Biosimilars Be in Rheumatology?

From conferences to seminars to education, biosimilars seems to be the talk of the town. Biologics have become the fastest growing class of medication and the biosimilar versions of the biologics used to treat rheumatoid arthritis (RA) and cancer will be able to cut healthcare spending drastically. 

The US Food and Drug Administration has approved nine biosimilar drugs to date — six of these to be used for rheumatology and other inflammatory diseases. Based on this information, biosimilars is often looked at as the future for rheumatology. However, according to a report by Practical Pain Management, that might not be the case. 

SOURCE: Practical Pain Management